Usefulness of endoscopic ultrasound with bronchoscope-guided fine-needle aspiration for next-generation sequencing in patients with non-small cell lung cancer: A comparison with other bronchoscopic techniques

IF 2.4 Q2 RESPIRATORY SYSTEM

Respiratory investigation Pub Date : 2024-08-02 DOI:10.1016/j.resinv.2024.07.012

Daisuke Himeji , Ritsuya Shiiba , Gen-ichi Tanaka , Akihisa Takano , Rikuto Kamiike , Natsumi Kushima , Shingo Matsumoto , Koichi Goto , Kazunari Maekawa , Kousuke Marutsuka

{"title":"Usefulness of endoscopic ultrasound with bronchoscope-guided fine-needle aspiration for next-generation sequencing in patients with non-small cell lung cancer: A comparison with other bronchoscopic techniques","authors":"Daisuke Himeji , Ritsuya Shiiba , Gen-ichi Tanaka , Akihisa Takano , Rikuto Kamiike , Natsumi Kushima , Shingo Matsumoto , Koichi Goto , Kazunari Maekawa , Kousuke Marutsuka","doi":"10.1016/j.resinv.2024.07.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Next-generation sequencing (NGS) is essential in treating advanced lung cancer. However, the effectiveness of endoscopic ultrasound with bronchoscope-guided fine-needle aspiration (EUS-B-FNA) in NGS remains unclear. This study examined the usefulness of EUS-B-FNA in lung cancer NGS cases where EUS-B-FNA was performed for specimen submission in a nationwide genomic screening platform (LC-SCRUM-Asia) and compared specimens collected using other bronchoscopy methods (endobronchial ultrasound-guided transbronchial needle aspiration [EBUS-TBNA] and EBUS-guided transbronchial biopsy with a guide sheath [EBUS-GS-TBB]) during the same period.</p></div><div><h3>Methods</h3><p>We retrospectively compared the NGS success rates of NGS, DNA and RNA yields for EUS-B-FNA, EBUS-TBNA, and EBUS-GS-TBB from the records of the patients recruited for the Lung Cancer Genomic Screening Project for Individualized Medicine (LC-SCRUM)-Asia.</p></div><div><h3>Results</h3><p>Fifty-one patients were enrolled, and the NGS success rates were comparable for samples obtained by EUS-B-FNA, EBUS-TBNA, and EBUS-GS-TBB (100%, 90.9%, and 81.0%, respectively). Genetic alterations were detected in 73.7%, 90.9%, and 85.7% of patients, respectively, with druggable genetic alterations found in 31.6%, 72.7%, and 61.9% of patients, respectively. The DNA and RNA yields were significantly higher in EUS-B-FNA samples than in EBUS-GS-TBB samples (50.4 (interquartile range (IR): 15.45–72.35) ng/μl and 33.9 (IR: 9–76.8) ng/μl from EUS-B-FNA, and 3.3 (IR: 1.4–7.1) ng/μl and 15.1 (IR: 8.3–31.5) ng/μl from EBUS-GS-TBB, respectively, <em>p</em> < 0.05).</p></div><div><h3>Conclusion</h3><p>EUS-B-FNA emerges as a promising bronchoscopic method for obtaining adequate samples for NGS in advanced lung cancer cases.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"62 5","pages":"Pages 879-883"},"PeriodicalIF":2.4000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory investigation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212534524001138","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Next-generation sequencing (NGS) is essential in treating advanced lung cancer. However, the effectiveness of endoscopic ultrasound with bronchoscope-guided fine-needle aspiration (EUS-B-FNA) in NGS remains unclear. This study examined the usefulness of EUS-B-FNA in lung cancer NGS cases where EUS-B-FNA was performed for specimen submission in a nationwide genomic screening platform (LC-SCRUM-Asia) and compared specimens collected using other bronchoscopy methods (endobronchial ultrasound-guided transbronchial needle aspiration [EBUS-TBNA] and EBUS-guided transbronchial biopsy with a guide sheath [EBUS-GS-TBB]) during the same period.

Methods

We retrospectively compared the NGS success rates of NGS, DNA and RNA yields for EUS-B-FNA, EBUS-TBNA, and EBUS-GS-TBB from the records of the patients recruited for the Lung Cancer Genomic Screening Project for Individualized Medicine (LC-SCRUM)-Asia.

Results

Fifty-one patients were enrolled, and the NGS success rates were comparable for samples obtained by EUS-B-FNA, EBUS-TBNA, and EBUS-GS-TBB (100%, 90.9%, and 81.0%, respectively). Genetic alterations were detected in 73.7%, 90.9%, and 85.7% of patients, respectively, with druggable genetic alterations found in 31.6%, 72.7%, and 61.9% of patients, respectively. The DNA and RNA yields were significantly higher in EUS-B-FNA samples than in EBUS-GS-TBB samples (50.4 (interquartile range (IR): 15.45–72.35) ng/μl and 33.9 (IR: 9–76.8) ng/μl from EUS-B-FNA, and 3.3 (IR: 1.4–7.1) ng/μl and 15.1 (IR: 8.3–31.5) ng/μl from EBUS-GS-TBB, respectively, p < 0.05).

Conclusion

EUS-B-FNA emerges as a promising bronchoscopic method for obtaining adequate samples for NGS in advanced lung cancer cases.

查看原文本刊更多论文

内窥镜超声与支气管镜引导下细针穿刺在非小细胞肺癌患者下一代测序中的应用：与其他支气管镜技术的比较。

背景：下一代测序（NGS）对治疗晚期肺癌至关重要。然而，内窥镜超声与支气管镜引导下细针穿刺术（EUS-B-FNA）在 NGS 中的有效性仍不明确。本研究考察了 EUS-B-FNA 在全国性基因组筛查平台（LC-SCRUM-Asia）中进行标本提交的肺癌 NGS 病例中的实用性，并比较了同期使用其他支气管镜方法（支气管内超声引导下经支气管针吸术 [EBUS-TBNA] 和 EBUS 引导下带导鞘经支气管活检术 [EBUS-GS-TBB]）收集的标本：我们回顾性比较了EUS-B-FNA、EBUS-TBNA和EBUS-GS-TBB的NGS成功率、DNA和RNA的产量，这些数据来自个性化医疗肺癌基因组筛查项目（LC-SCRUM）-亚洲的患者记录：结果：51 名患者入组，通过 EUS-B-FNA、EBUS-TBNA 和 EBUS-GS-TBB 获得的样本的 NGS 成功率相当（分别为 100%、90.9% 和 81.0%）。分别有 73.7%、90.9% 和 85.7% 的患者检测到基因改变，其中分别有 31.6%、72.7% 和 61.9% 的患者发现可药物治疗的基因改变。EUS-B-FNA样本的DNA和RNA产量明显高于EBUS-GS-TBB样本（EUS-B-FNA分别为50.4（四分位距（IR）：15.45-72.35）纳克/微升和33.9（IR：9-76.8）纳克/微升，而EBUS-GS-TBB分别为3.3（IR：1.4-7.1）纳克/微升和15.1（IR：8.3-31.5）纳克/微升）：EUS-B-FNA 是一种很有前景的支气管镜方法，可为晚期肺癌病例的 NGS 采集足够的样本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Respiratory investigation RESPIRATORY SYSTEM-

CiteScore

4.90

自引率

6.50%

发文量

114

审稿时长

64 days